Navigation Links
EVMS receives more than $1 million in federal funds to develop new ways to reverse type 1 diabetes
Date:3/25/2010

Researchers at the Eastern Virginia Medical School Strelitz Diabetes Center have been awarded a $1,076,250 grant by the Department of Defense (DoD) Peer Reviewed Medical Research Program to develop new ways of reversing the underlying causes of Type 1 diabetes.

David Taylor-Fishwick, PhD, associate professor of internal medicine and director of the Cell, Molecular and Islet Biology Laboratory, leads the team whose research applies to both regenerative and autoimmune medicine.

"Type 1 diabetes is caused by an autoimmune attack that destroys the insulin-producing beta cells, and the body does not automatically regenerate or replace these cells," explains Dr. Taylor-Fishwick. "The unique challenge in reversing Type 1 diabetes is to regenerate the insulin-producing beta cells and to stop the body's autoimmune attack."

Insulin is the hormone that helps the body convert glucose from food into energy. When the beta cells are destroyed, no insulin can be produced. Insulin replacement therapy helps the body maintain normal glucose levels, but doesn't prevent the serious diabetes health problems such as blindness, nerve damage, heart disease and kidney failure.

Dr. Taylor-Fishwick's research on beta cell regeneration has focused on INGAP (Islet Neogenesis Associated Protein), branded as Exsulin, the breakthrough discovery made by Aaron I. Vinik, PhD, MD, director of research at the Strelitz Diabetes Center, and Dr. Lawrence Rosenberg of McGill University. Published trials of Exsulin demonstrated promising results in both Type 1 and Type 2 diabetes patients.

The DoD grant will fund the next phase in the team's research finding a way to neutralize the immune system's attack of the beta cells. This immune attack occurs at the onset of diabetes and may continue after Type 1 diabetes has appeared. The benefits of this research may also apply to other autoimmune diseases such as lupus and rheumatoid arthritis.

Dr. Taylor-Fishwick and his team will test several experimental drugs developed by Jerry Nadler, MD, chair of internal medicine and director of the EVMS Strelitz Diabetes Center. The compounds are designed to modify the autoimmune response and stabilize beta cells. The goal is to develop these compounds into an oral pill.

"The Department of Defense, through its Congressionally Directed Medical Research Program, is especially interested in research to combat autoimmunity," Dr. Taylor-Fishwick says. "So part of our work is to block the process of autoimmunity that occurs in diabetes. We are using a drug called Lisofylline (LSF) and related molecules to block interleukin-12, a protein that triggers the autoimmune response," he explains. "By targeting interleukin-12 signaling, we hope to redirect the immune system, but not wipe it out."

The researchers hope that one of these compounds, when used in conjunction with Exsulin, may help to create a combination therapy regimen that could achieve a functional cure for Type 1 diabetes.


'/>"/>

Contact: Jina Gaines
gainesjn@evms.edu
757-446-7070
Eastern Virginia Medical School
Source:Eurekalert  

Related medicine news :

1. US Wellness, Inc. Receives National Recognition for Laboratory Excellence
2. American Public Health Champion Receives 2010 Stockholm Water Prize
3. Society for New Communications Research Receives Grant to Help Raise Awareness and Reduce Racial and Ethnic Health Disparities
4. BUSM researcher receives prestigious young investigator award
5. Yondelis(R) Receives Five New Approvals Outside the European Economic Area
6. Christiana Care Health Systems Darcy Burbage Receives Oncology Nursing Society Award
7. Moleac Receives BioSpectrum Asia Emerging Company of the Year 2010 Award
8. CoreObjects Receives Project Management Institutes Excellence Award for Diabetes Contribution
9. Zimmer Receives Recognition for Health Economics Data Presented at 77th Annual American Academy of Orthopaedic Surgeons Meeting
10. U.S. Senator Kit Bond Receives 2010 AOA Health Care Leadership Award
11. Intellimed's Popular Data Reporting Software IM-IC (Intelligent Client) Receives Latest Update
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
EVMS receives more than $1 million in federal funds to develop new ways to reverse type 1 diabetes
(Date:4/21/2017)... ... April 21, 2017 , ... Northern California ... Primary Care Spring Symposium on April 1, 2017 in Santa Rosa. This well-attended ... and healthcare providers an opportunity to learn about cutting edge treatments, to collaborate, ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... candidates to serve on its Accreditation and Standards Committees to support the ... is improving image quality and reducing patient radiation dose,” reports Eliot Siegel, ...
(Date:4/21/2017)... ... April 21, 2017 , ... BrightStar Care Salt Lake City, a home care ... Utah (APCUT) and has appointed Rex Wheeler as its new Director of Business Development. ... agency and our ability to provide quality care to the community,” said Tammara Brown, ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... world leaders in hopes of squashing a global crisis with solution to peace plan. Yisrayl ... to work because the plan is given by the Creator Himself. , Yisrayl says ...
(Date:4/21/2017)... ... April 21, 2017 , ... During April 21-23, Super-Sod will join ... This festival offers entertainment for everyone — from the avid gardener to the landscape ... very high quality event held in a grand venue, and we are certainly looking ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017 Research and ... Biosimilar Pipeline and Market Prospects: Addressing Production Complexities Through ... their offering. ... "Global Biosimilar Pipeline and Market Prospects: Overcoming Production ... an in-depth assessment of the current trends in the ...
(Date:4/20/2017)... April 20, 2017 Research and Markets has ... Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage of ... ... delivery technologies will rise from USD 20 Billion in 2015 to ... Drug Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables Market ...
(Date:4/20/2017)... Inc ., a digital health company focused on modernizing and ... $25 million in Series B funding led by Qiming US ... Seattle that is part of a broader family ... included participation from SR One , who led ZappRx,s ... Google Ventures). As part of the financing, Mark McDade ...
Breaking Medicine Technology: